KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Payables: 2009-2024

Historic Payables for Idexx Laboratories (IDXX) over the last 16 years, with Dec 2024 value amounting to $114.2 million.

  • Idexx Laboratories' Payables rose 10.54% to $122.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.2 million, marking a year-over-year increase of 3.72%. This contributed to the annual value of $114.2 million for FY2024, which is 3.22% up from last year.
  • As of FY2024, Idexx Laboratories' Payables stood at $114.2 million, which was up 3.22% from $110.6 million recorded in FY2023.
  • Idexx Laboratories' Payables' 5-year high stood at $116.1 million during FY2021, with a 5-year trough of $74.6 million in FY2020.
  • Over the past 3 years, Idexx Laboratories' median Payables value was $110.6 million (recorded in 2023), while the average stood at $111.7 million.
  • As far as peak fluctuations go, Idexx Laboratories' Payables skyrocketed by 55.77% in 2021, and later dropped by 5.10% in 2022.
  • Yearly analysis of 5 years shows Idexx Laboratories' Payables stood at $74.6 million in 2020, then skyrocketed by 55.77% to $116.1 million in 2021, then decreased by 5.10% to $110.2 million in 2022, then increased by 0.38% to $110.6 million in 2023, then climbed by 3.22% to $114.2 million in 2024.